HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a $6 price target.
November 06, 2023 | 11:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clearside Biomedical's stock has been reiterated as a 'Buy' by HC Wainwright & Co. with a maintained price target of $6.
The reiteration of a 'Buy' rating and a maintained price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Clearside Biomedical. This could potentially lead to an increase in investor confidence and a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100